Publicacions (84) Publicacions de Edel del Barco Morillo

2024

  1. COMPLICATIONS SECONDARY TO THE USE OF SGLT2 INHIBITORS IN ONCOLOGICAL PATIENTS: A SERIES OF 5 CASES

    European Journal of Case Reports in Internal Medicine, Vol. 11, Núm. 1

  2. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  3. Cuidados continuos en Oncología (I): generalidades

    Oncología clínica (Arán Ediciones), pp. 147-155

  4. Cuidados continuos en oncología (II): control de los principales síntomas y del dolor, cuidados en el final de la vida, duelo

    Oncología clínica (Arán Ediciones), pp. 157-173

  5. Cuidados continuos en oncología (III): infecciones en el paciente con cáncer, neutropenia febril

    Oncología clínica (Arán Ediciones), pp. 175-188

  6. Cáncer de cabeza y cuello

    Oncología clínica (Arán Ediciones), pp. 259-271

  7. Cáncer de pulmón

    Oncología clínica (Arán Ediciones), pp. 227-257

  8. Diagnóstico nosológico y de extensión. Factores pronósticos

    Oncología clínica (Arán Ediciones), pp. 59-71

  9. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  10. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology

  11. Oncología clínica coord.

    Arán Ediciones

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

    Precision Cancer Medicine

  3. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

    Cancers, Vol. 15, Núm. 17

  4. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  5. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

    Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128

  6. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck

    Frontiers in Oncology, Vol. 13

  7. The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients

    Diagnostics, Vol. 13, Núm. 14

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71